{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:04:35Z","timestamp":1785074675407,"version":"3.55.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108274","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:34:21Z","timestamp":1780122861000},"page":"108274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adenosine receptors in blood cells: Biomarkers and beyond"],"prefix":"10.1016","volume":"230","author":[{"given":"Stefania","family":"Merighi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-1348","authenticated-orcid":false,"given":"Katia","family":"Varani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Andrea","family":"Borea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-5611","authenticated-orcid":false,"given":"Stefania","family":"Gessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108274_bib1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/pr10061107","article-title":"Making biomarkers relevant to healthcare innovation and precision medicine","volume":"10","author":"Al-Dewik","year":"2022","journal-title":"Processes"},{"key":"10.1016\/j.phrs.2026.108274_bib2","article-title":"Biomarkers in translational biomedicine: research and clinical practice","volume":"15","author":"Illa","year":"2024","journal-title":"Transl. Biomed."},{"key":"10.1016\/j.phrs.2026.108274_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0165-6147(87)90108-8","article-title":"Human heart \u03b2-adrenoceptors: a fair comparison with lymphocyte \u03b2-adrenoceptors?","volume":"8","author":"Brodde","year":"1987","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2026.108274_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10238-024-01294-3","article-title":"The diagnostic role of the systemic inflammation index in patients with immunological diseases: a systematic review and meta-analysis","volume":"24","author":"Mangoni","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.phrs.2026.108274_bib5","first-page":"95","article-title":"Biomarkers in immunology: their impact on immune function and response","volume":"7","author":"Kaushik","year":"2025","journal-title":"Adv. Biomark. Sci. Technol."},{"key":"10.1016\/j.phrs.2026.108274_bib6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2026.108274_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcp.2018.02.002","article-title":"Adenosine metabolism, immunity and joint health","volume":"151","author":"Hask\u00f3","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","article-title":"International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update","volume":"74","author":"IJzerman","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2026.108274_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects?","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2026.108274_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.bjp.0703045","article-title":"A2A adenosine receptors in human peripheral blood cells","volume":"129","author":"Gessi","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100092","article-title":"Targeting the adenosinergic axis in cancer immunotherapy: insights into A2A and A2B receptors and novel clinical combination strategies","volume":"77","author":"Rodr\u00edguez-Pamp\u00edn","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2026.108274_bib12","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3390\/molecules27123680","article-title":"Drugs targeting the A3 adenosine receptor: human clinical study data","volume":"27","author":"Fishman","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108274_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41388-021-02090-z","article-title":"Cancer biology and molecular genetics of A3 adenosine receptor","volume":"41","author":"Mazziotta","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2026.108274_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41423-020-00632-1","article-title":"Increased expression of adenosine A3 receptor in tumor-infiltrating natural killer cells","volume":"18","author":"Bi","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.phrs.2026.108274_bib15","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-1134-03","article-title":"Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer Is Reflected in Peripheral Blood Cells","volume":"10","author":"Gessi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108274_bib16","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1158\/1078-0432.CCR-03-0651","article-title":"The A3 Adenosine Receptor Is Highly Expressed in Tumor versus Normal Cells","volume":"10","author":"Madi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108274_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1164\/rccm.201006-0980OC","article-title":"A3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt\/nuclear factor-\u03baB pathway","volume":"183","author":"Varani","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2026.108274_bib18","first-page":"20","article-title":"Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-\u03baB in mediating receptor level","volume":"34","author":"Madi","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108274_bib19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","article-title":"Regadenoson: a new myocardial stress agent","volume":"54","author":"Al Jaroudi","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib20","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.2174\/0929867328666211129122550","article-title":"A2A adenosine receptor antagonists in neurodegenerative diseases","volume":"29","author":"Merighi","year":"2022","journal-title":"CMC"},{"key":"10.1016\/j.phrs.2026.108274_bib21","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3390\/jcm14061860","article-title":"Assessing the real-world safety of regadenoson for myocardial perfusion imaging: insights from a comprehensive analysis of FAERS data","volume":"14","author":"Xu","year":"2025","journal-title":"JCM"},{"key":"10.1016\/j.phrs.2026.108274_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108274_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets \u2014 what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108274_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"DDDT"},{"key":"10.1016\/j.phrs.2026.108274_bib25","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3390\/biom13111584","article-title":"Namodenoson inhibits the growth of pancreatic carcinoma via deregulation of the Wnt\/\u03b2-catenin, NF-\u03baB, and RAS signaling pathways","volume":"13","author":"Itzhak","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108274_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3892\/etm.2024.12551","article-title":"A long\u2011term complete response to namodenoson in liver cancer with Child\u2011Pugh B cirrhosis: a case report","volume":"27","author":"Ciurescu","year":"2024","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phrs.2026.108274_bib27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/biomedicines12040848","article-title":"Namodenoson at the crossroad of metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma","volume":"12","author":"Etzion","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108274_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add3709","article-title":"Cryo-EM structure of the human adenosine A2B receptor\u2013Gs signaling complex","volume":"8","author":"Chen","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2026.108274_bib29","doi-asserted-by":"crossref","first-page":"7674","DOI":"10.1038\/s41467-025-62872-x","article-title":"Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108274_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/jcbfm.1993.93","article-title":"Adenosine, a \u201cRetaliatory\u201d Metabolite, Promotes Anoxia Tolerance in Turtle Brain","volume":"13","author":"P\u00e9rez-Pinz\u00f3n","year":"1993","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.phrs.2026.108274_bib31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00011-022-01607-w","article-title":"The role of adenosine A1 receptor on immune cells","volume":"71","author":"Zhong","year":"2022","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.phrs.2026.108274_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41589-024-01682-6","article-title":"Balancing G protein selectivity and efficacy in the adenosine A2A receptor","volume":"21","author":"Picard","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108274_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11302-025-10070-1","article-title":"A2B adenosine receptor-triggered intracellular calcium mobilization: cell type-dependent involvement of Gi, Gq, Gs proteins and protein kinase C","volume":"21","author":"Gao","year":"2025","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.phrs.2026.108274_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2017.12.003","article-title":"On the G protein-coupling selectivity of the native A2B adenosine receptor","volume":"151","author":"Gao","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11302-024-10025-y","article-title":"A2B adenosine receptor signaling and regulation","volume":"21","author":"Gao","year":"2025","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.phrs.2026.108274_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/pr.113.008540","article-title":"The A3 Adenosine Receptor: History and Perspectives","volume":"67","author":"Borea","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2026.108274_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2026.108274_bib38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11302-022-09910-1","article-title":"Species dependence of A3 adenosine receptor pharmacology and function","volume":"19","author":"Gao","year":"2023","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.phrs.2026.108274_bib39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0898-6568(03)00058-5","article-title":"Signalling from adenosine receptors to mitogen-activated protein kinases","volume":"15","author":"Schulte","year":"2003","journal-title":"Cell. Signal."},{"key":"10.1016\/j.phrs.2026.108274_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2003.08.031","article-title":"Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1\/2 via phosphatidylinositol-3\u2032-kinase","volume":"67","author":"Hammarberg","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.phrs.2026.108274_bib42","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1074\/jbc.M413279200","article-title":"cAMP-response Element-binding Protein Contributes to Suppression of the A2A Adenosine Receptor Promoter by Mutant Huntingtin with Expanded Polyglutamine Residues","volume":"280","author":"Chiang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108274_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/caff.2018.0006","article-title":"The role of adenosine tone and adenosine receptors in huntington\u2019s disease","volume":"8","author":"Blum","year":"2018","journal-title":"J. Caffeine Aden Res."},{"key":"10.1016\/j.phrs.2026.108274_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12017-013-8219-0","article-title":"Increased 5-Methylcytosine and Decreased 5-Hydroxymethylcytosine Levels are Associated with Reduced Striatal A2AR Levels in Huntington\u2019s Disease","volume":"15","author":"Villar-Men\u00e9ndez","year":"2013","journal-title":"Neuromol Med."},{"key":"10.1016\/j.phrs.2026.108274_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2017.00017","article-title":"Contribution of neuroepigenetics to huntington\u2019s disease","volume":"11","author":"Francelle","year":"2017","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.phrs.2026.108274_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.03-0079fje","article-title":"Aberrant A2A receptor function in peripheral blood cells in Huntington\u2019s disease","volume":"17","author":"Varani","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108274_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2005.09.037","article-title":"The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington\u2019s disease patients with predominant chorea","volume":"393","author":"Maglione","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2026.108274_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2007.03.011","article-title":"Biological abnormalities of peripheral A2A receptors in a large representation of polyglutamine disorders and Huntington\u2019s disease stages","volume":"27","author":"Varani","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108274_bib49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nbd.2006.01.014","article-title":"Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease","volume":"23","author":"Tarditi","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108274_bib50","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00415-023-11572-x","article-title":"The updated development of blood-based biomarkers for Huntington\u2019s disease","volume":"270","author":"Zhang","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.phrs.2026.108274_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/biology14020129","article-title":"Advances in Huntington\u2019s Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review","volume":"14","author":"Aqel","year":"2025","journal-title":"Biology"},{"key":"10.1016\/j.phrs.2026.108274_bib52","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2026.108274_bib53","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108274_bib54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1096\/fj.09-141044","article-title":"A2A adenosine receptor overexpression and functionality, as well as TNF-\u03b1 levels, correlate with motor symptoms in Parkinson\u2019s disease","volume":"24","author":"Varani","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108274_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010749","article-title":"Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease","volume":"95","author":"Fanciulli","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2026.108274_bib56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fnins.2019.00683","article-title":"On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson\u2019s Disease","volume":"13","author":"Falconi","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.phrs.2026.108274_bib57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jacc.2015.04.066","article-title":"Adenosine and clinical forms of neurally-mediated syncope","volume":"66","author":"Guieu","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuropharm.2015.05.028","article-title":"Allosteric mechanisms within the adenosine A2A\u2013dopamine D2 receptor heterotetramer","volume":"104","author":"Ferr\u00e9","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108274_bib59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ane.12181","article-title":"A2A adenosine receptors and Parkinson\u2019s disease severity","volume":"129","author":"Casetta","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.phrs.2026.108274_bib60","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/molecules27072366","article-title":"The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson\u2019s Disease","volume":"27","author":"Mori","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108274_bib61","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1007\/s12035-023-03257-3","article-title":"Adenosinergic Pathway in Parkinson\u2019s Disease: Recent Advances and Therapeutic Perspective","volume":"60","author":"Zhao","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108274_bib62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108274_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.946698","article-title":"The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis","volume":"13","author":"Duarte-Silva","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108274_bib64","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/jcbfm.2013.85","article-title":"Adenosine A2A receptors in secondary progressive multiple sclerosis: a [11C]TMSX Brain PET Study","volume":"33","author":"Rissanen","year":"2013","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.phrs.2026.108274_bib65","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/eji.201343314","article-title":"Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated","volume":"43","author":"Vincenzi","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.phrs.2026.108274_bib66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cardfail.2004.04.005","article-title":"Upregulation of A2A adenosine receptor expression by TNF-\u03b1 in PBMC of patients with CHF: a regulatory mechanism of inflammation","volume":"11","author":"Capecchi","year":"2005","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.phrs.2026.108274_bib67","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.4049\/jimmunol.177.10.7173","article-title":"IL-1\u03b2 and TNF-\u03b1 Regulation of the Adenosine Receptor (A2A) Expression: Differential Requirement for NF-\u03baB Binding to the Proximal Promoter","volume":"177","author":"Morello","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108274_bib68","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/BJ20050888","article-title":"Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-\u03baB in A2A adenosine receptor induction","volume":"391","author":"Murphree","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2026.108274_bib69","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1189\/jlb.0607359","article-title":"A2A receptors in inflammation and injury: lessons learned from transgenic animals","volume":"83","author":"Hask\u00f3","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2026.108274_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2026.103389","article-title":"Adenosine A\u2082A receptor as a dual-acting molecular switch: Glial morphological changes and neurovascular tissue remodeling in neuroinflammation and neurodegeneration","volume":"100","author":"El-Moaty","year":"2026","journal-title":"Tissue Cell."},{"key":"10.1016\/j.phrs.2026.108274_bib71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Sig Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108274_bib72","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cells9051075","article-title":"Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer\u2019s Disease","volume":"9","author":"Franco","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108274_bib73","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41380-018-0110-9","article-title":"Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors","volume":"25","author":"Temido-Ferreira","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108274_bib74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11302-022-09883-1","article-title":"Adenosine receptor signalling in Alzheimer\u2019s disease","volume":"18","author":"Trinh","year":"2022","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.phrs.2026.108274_bib75","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1007\/s12035-023-03441-5","article-title":"Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach","volume":"60","author":"Karati","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108274_bib76","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/brain\/awae113","article-title":"Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP\/PS1 mice","volume":"147","author":"Gomez-Murcia","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108274_bib77","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1038\/s41380-025-03115-9","article-title":"Upregulation of adenosine A2A receptor in astrocytes is sufficient to trigger hippocampal multicellular dysfunctions and memory deficits","volume":"30","author":"Launay","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108274_bib78","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1007\/s11357-025-01526-8","article-title":"Blockade of A2AR improved brain perfusion and cognitive function in a mouse model of Alzheimer\u2019s disease","volume":"47","author":"Udo","year":"2025","journal-title":"GeroScience"},{"key":"10.1016\/j.phrs.2026.108274_bib79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/acschemneuro.5c00827","article-title":"Development of a Novel PET Radioligand for Imaging the Adenosine A2A Receptor in the Brain","volume":"17","author":"Wang","year":"2026","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2026.108274_bib80","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.3233\/JAD-2010-1404","article-title":"Caffeine as a protective factor in dementia and Alzheimer\u2019s disease","volume":"20","author":"Eskelinen","year":"2010","journal-title":"JAD"},{"key":"10.1016\/j.phrs.2026.108274_bib81","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.3233\/JAD-2010-091249","article-title":"Caffeine and coffee as therapeutics against Alzheimer\u2019s disease","volume":"20","author":"Arendash","year":"2010","journal-title":"JAD"},{"key":"10.1016\/j.phrs.2026.108274_bib82","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-201437","article-title":"Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer\u2019s Disease","volume":"80","author":"Merighi","year":"2021","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.phrs.2026.108274_bib83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1750-3639.2003.tb00475.x","article-title":"A1 Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer\u2019s Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation","volume":"13","author":"Angulo","year":"2003","journal-title":"Brain Pathol."},{"key":"10.1016\/j.phrs.2026.108274_bib84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-3639.2007.00112.x","article-title":"Research article: up-regulation of adenosine receptors in the frontal cortex in Alzheimer\u2019s disease","volume":"18","author":"Albasanz","year":"2008","journal-title":"Brain Pathol."},{"key":"10.1016\/j.phrs.2026.108274_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-131652","article-title":"Different Adenosine A2A Receptor Expression in Peripheral Cells from Elderly Patients with Vascular Dementia and Alzheimer\u2019s Disease","volume":"40","author":"Gussago","year":"2014","journal-title":"JAD"},{"key":"10.1016\/j.phrs.2026.108274_bib86","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/cells14201585","article-title":"Adenosine receptors in neuroinflammation and neurodegeneration","volume":"14","author":"Salmaso","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108274_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.702581","article-title":"Adenosine A2A Receptors as Biomarkers of Brain Diseases","volume":"15","author":"Moreira-de-S\u00e1","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.phrs.2026.108274_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.627838","article-title":"Role of Cardiac A2A Receptors Under Normal and Pathophysiological Conditions","volume":"11","author":"Boknik","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1538680","article-title":"Adenosine and adenosine receptors: a \u201cdouble-edged sword\u201d in cardiovascular system","volume":"16","author":"Qian","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077025","article-title":"Advances in management of heart failure","volume":"385","author":"Heidenreich","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2026.108274_bib91","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1096\/fj.02-0543fje","article-title":"Changes of peripheral A2A adenosine receptors in chronic heart failure and cardiac transplantation","volume":"17","author":"Varani","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108274_bib92","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108274_bib93","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijcard.2016.12.089","article-title":"Expressions of adenosine A2A receptors in coronary arteries and peripheral blood mononuclear cells are correlated in coronary artery disease patients","volume":"230","author":"Gariboldi","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2014.11.089","article-title":"Low basal expression of A2A adenosine receptors and increase in adenosine plasma concentration are associated with positive exercise stress testing","volume":"180","author":"Guieu","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib95","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/biomedicines10081849","article-title":"Plasma A2AR Measurement Can Help Physicians Identify Patients Suspected of Coronary Chronic Syndrome: A Pilot Study","volume":"10","author":"Paganelli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108274_bib96","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1111\/jcmm.15527","article-title":"Homocysteine concentration and adenosine A2A receptor production by peripheral blood mononuclear cells in coronary artery disease patients","volume":"24","author":"Deharo","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108274_bib97","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2019.02.055","article-title":"Pharmacological profile of adenosine A2A receptors in patients with lower extremity peripheral artery disease and associated coronary artery disease: a pilot study","volume":"285","author":"Gaudry","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib98","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cjco.2025.06.024","article-title":"Pharmacologic Profile of A2A Adenosine Receptors: Identifying Patients with Intermittent Claudication and Associated Myocardial Ischemia","volume":"7","author":"Deharo","year":"2025","journal-title":"CJC Open."},{"key":"10.1016\/j.phrs.2026.108274_bib99","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/cells13060488","article-title":"Low Density Lipoprotein Cholesterol Decreases the Expression of Adenosine A2A Receptor and Lipid Rafts-Protein Flotillin-1: Insights on Cardiovascular Risk of Hypercholesterolemia","volume":"13","author":"Chaptal","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108274_bib100","unstructured":"Assistance Publique Hopitaux De Marseille, Role of A2A Receptor in Hypercholesterolemic Patients (RASCAS), 2023. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05017649\u3009."},{"key":"10.1016\/j.phrs.2026.108274_bib101","article-title":"New recommendations for rhythm control\u2014What has changed in the 2023 ACC\/AHA\/ACCP\/HRS and 2024 ESC guidelines for atrial fibrillation, and where does dronedarone fit in?","volume":"60","author":"Naccarelli","year":"2025","journal-title":"Am. Heart J. Cardiol. Res. Pract."},{"key":"10.1016\/j.phrs.2026.108274_bib102","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.3390\/ijms22073467","article-title":"Adenosine A2A Receptors Are Upregulated in Peripheral Blood Mononuclear Cells from Atrial Fibrillation Patients","volume":"22","author":"Godoy-Mar\u00edn","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.phrs.2026.108274_bib103","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.3390\/ijms24043668","article-title":"Increased Density of Endogenous Adenosine A2A Receptors in Atrial Fibrillation: From Cellular and Porcine Models to Human Patients","volume":"24","author":"Godoy-Mar\u00edn","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.phrs.2026.108274_bib104","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cardiores.2006.07.020","article-title":"Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release","volume":"72","author":"Hovemadsen","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2026.108274_bib105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/eurheartj\/ehq464","article-title":"Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors","volume":"32","author":"Llach","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2026.108274_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.761164","article-title":"A2 adenosine receptor subtypes overproduction in atria of perioperative atrial fibrillation patients undergoing cardiac surgery: a pilot study","volume":"8","author":"Maille","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2026.108274_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/2310970","article-title":"Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson","volume":"2018","author":"Cohen","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.phrs.2026.108274_bib108","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.3390\/ijms25115810","article-title":"Adenosine and its receptors in the pathogenesis and treatment of inflammatory skin diseases","volume":"25","author":"Chen","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.phrs.2026.108274_bib109","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2009.11.029","article-title":"Treatment of Dry Eye Syndrome with Orally Administered CF101","volume":"117","author":"Avni","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2026.108274_bib110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial","volume":"26","author":"David","year":"2012","journal-title":"Acad. Dermatol. Venereol."},{"key":"10.1016\/j.phrs.2026.108274_bib111","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/jacs.4c13558","article-title":"Photoswitchable Diazocine Derivative for Adenosine A3 Receptor Activation in Psoriasis","volume":"147","author":"L\u00f3pez-Cano","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.108274_bib112","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cellimm.2009.03.020","article-title":"The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn\u2019s disease","volume":"258","author":"Ochaion","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.phrs.2026.108274_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105731","article-title":"Optical control of adenosine A3 receptor function in psoriasis","volume":"170","author":"L\u00f3pez-Cano","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108274_bib114","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jdv.19811","article-title":"the COMFORT-1 Study Investigators, Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial ( COMFORT -1)","volume":"38","author":"Papp","year":"2024","journal-title":"Acad. Dermatol. Venereol."},{"key":"10.1016\/j.phrs.2026.108274_bib115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108274_bib116","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2174\/1381612825666190710111658","article-title":"Perspective and Potential of A2A and A3 Adenosine Receptors as Therapeutic Targets for the Treatment of Rheumatoid Arthritis","volume":"25","author":"Pal","year":"2019","journal-title":"CPD"},{"key":"10.1016\/j.phrs.2026.108274_bib117","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.2174\/1381612825666190716145206","article-title":"Role and function of adenosine and its receptors in inflammation, neuroinflammation, IBS, autoimmune inflammatory disorders, rheumatoid arthritis and psoriasis","volume":"25","author":"Shakya","year":"2019","journal-title":"CPD"},{"key":"10.1016\/j.phrs.2026.108274_bib118","doi-asserted-by":"crossref","DOI":"10.1186\/ar3527","article-title":"A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release","volume":"13","author":"Varani","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2026.108274_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054195","article-title":"A2A adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats","volume":"8","author":"Vincenzi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2026.108274_bib120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/ijms18040697","article-title":"Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis","volume":"18","author":"Ravani","year":"2017","journal-title":"IJMS"},{"key":"10.1016\/j.phrs.2026.108274_bib121","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1038\/s41598-022-10012-6","article-title":"Adenosine inhibits TNF\u03b1-induced MMP-3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling","volume":"12","author":"Konishi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108274_bib122","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bcp.2008.05.032","article-title":"The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB\/Akt and NF-\u03baB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats","volume":"76","author":"Ochaion","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib123","first-page":"41","article-title":"Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial","volume":"35","author":"Silverman","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2026.108274_bib124","doi-asserted-by":"crossref","first-page":"20418","DOI":"10.1039\/D5RA02235E","article-title":"Therapeutic potential of adenosine receptor modulators in cancer treatment","volume":"15","author":"Maity","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.phrs.2026.108274_bib125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lfs.2016.10.008","article-title":"Role of adenosine A2b receptor overexpression in tumor progression","volume":"166","author":"Sep\u00falveda","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2026.108274_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.826","article-title":"Role of adenosine A2a receptor in cancers and autoimmune diseases","volume":"11","author":"Ye","year":"2023","journal-title":"Immun. Inflam. Dis."},{"key":"10.1016\/j.phrs.2026.108274_bib127","article-title":"Overexpression of adenosine receptor (A1, A2a, A2b, A3) genes in esophageal tumor tissue: A2b adenosine receptor as a potential biomarker and anticancer target","author":"Poorjam","year":"2025","journal-title":"J. Appl. Genet."},{"key":"10.1016\/j.phrs.2026.108274_bib128","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-801022-8.00003-9","article-title":"An Overview of Adenosine A2A Receptor Antagonists in Parkinson\u2019s Disease","author":"Jenner","year":"2014"},{"key":"10.1016\/j.phrs.2026.108274_bib129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A2A receptor antagonist treatment of Parkinson\u2019s disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2026.108274_bib130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0000000000000073","article-title":"A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease","volume":"38","author":"Kondo","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2026.108274_bib131","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","article-title":"Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations","volume":"23","author":"Hauser","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2026.108274_bib132","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","article-title":"The Japanese Istradefylline Study Group, Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: A randomized, controlled study","volume":"25","author":"Mizuno","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2026.108274_bib133","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737175.2021.1880896","article-title":"Istradefylline \u2013 a first generation adenosine A2A antagonist for the treatment of Parkinson\u2019s disease","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.phrs.2026.108274_bib134","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-3565(24)29370-8","article-title":"Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists","volume":"298","author":"Gao","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2026.108274_bib135","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0091270007301620","article-title":"Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal Function","volume":"47","author":"Gordi","year":"2007","journal-title":"J. Clin. Pharma"},{"key":"10.1016\/j.phrs.2026.108274_bib136","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nuclcard.2007.02.016","article-title":"Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans","volume":"14","author":"Lieu","year":"2007","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib137","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J. Nucl. Cardiol."},{"key":"10.1016\/j.phrs.2026.108274_bib138","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10554-021-02363-4","article-title":"Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry","volume":"38","author":"Monmeneu Menadas","year":"2022","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"10.1016\/j.phrs.2026.108274_bib139","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.12940","article-title":"Regadenoson stress testing: a comprehensive review with a focused update","author":"Elkholy","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2026.108274_bib140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.drudis.2011.10.007","article-title":"Pharmacological and therapeutic effects of A3 adenosine receptor agonists","volume":"17","author":"Fishman","year":"2012","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.phrs.2026.108274_bib141","first-page":"287","article-title":"The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways","volume":"33","author":"Bar-Yehuda","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2026.108274_bib142","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00403-024-03506-y","article-title":"Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"317","author":"Ul Haq","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.phrs.2026.108274_bib143","article-title":"The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study","volume":"73","author":"Reitblat","year":"2021","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2026.108274_bib144","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/cancers13020187","article-title":"Namodenoson in Advanced Hepatocellular Carcinoma and Child\u2013Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial","volume":"13","author":"Stemmer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2026.108274_bib145","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:56:03Z","timestamp":1785074163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":145,"alternative-id":["S1043661826001891"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108274","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenosine receptors in blood cells: Biomarkers and beyond","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108274"}}